Historique
Périodique
Physiochemical and pharmacological characterization of a delta 9-THC aerosol generated by a metered dose inhaler
(Caractéristiques physiologiques et pharmacologiques d'un aérosol de delta9-THC généré par un inhalateur)
Auteur(s) :
WILSON, D. M. ;
PEART J. ;
MARTIN, B. R. ;
BRIDGEN D. T. ;
BYRON P. R. ;
LICHTMAN, A. H.
Année
2002
Page(s) :
259-267
Langue(s) :
Anglais
Refs biblio. :
41
Domaine :
Drogues illicites / Illicit drugs
Discipline :
PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)
Thésaurus mots-clés
TETRAHYDROCANNABINOL
;
CANNABINOIDES
;
INHALATION
;
MECANISME D'ACTION
;
USAGE THERAPEUTIQUE
;
MODELE ANIMAL
Note générale :
Drug and Alcohol Dependence, 2002, 67, (3), 259-267
Note de contenu :
graph. ; tabl.
Résumé :
ENGLISH :
The goal of the present study was to formulate a delta9-tetrahydrocannabinol (delta9-THC) metered-dose inhaler (MDI) that can be used to provide a systemic dose of delta9-THC via inhalation. Following physiochemical characterization and accelerated stability testing of the aerosol, mice were exposed to the aerosol and evaluated for pharmacological effects indicative of cannabinoid activity, including hypomotility, antinociception, catalepsy, and hypothermia. The fine particle dose of delta9-THC was 022+0.03 mg (mean+S,D.) or 25% of the emitted dose and was not affected by accelerated stability testing. A 10-min exposure to aerosolized delta9-THC elicited hypomotility, antinociception, catalepsy, and hypothermia. Additionally, delta9-THC concentrations in blood and brain at the antinociceptive ED50 dose were similar for both inhalation and intravenous routes of administration. Finally, pretreatment with the CB1 receptor antagonist SR 141716A (10 mg/kg, i.p.) significantly antagonized all of the D9-THC-induced effects. These results indicate that an MDI is a viable method to deliver a systemic dose of delta9-THC that elicits a full spectrum of cannabinoid pharmacological effects in mice that is mediated via a CB, receptor mechanism of action. Further development of a delta9-THC MDI could provide an appropriate delivery device for the therapeutic use of cannabinoids, thereby reducing the need for medicinal marijuana. (Review's abstract.)
Affiliation :
Dept. Pharmacol. Toxicol.,Virginia Commonwealth Univ., PO Box 980613, Richmond, VA 23298
Etats-Unis. United States.
Etats-Unis. United States.